Napo Pharmaceuticals, Inc. develops and commercializes proprietary pharmaceuticals for international markets. It offers Crofelemer for gastrointestinal indications, including chronic diarrhea in persons living with HIV/AIDS; and NP-500, a product for insulin-resistant diseases. The company also provides CRO-IBS for diarrhea-predominant IBS; CRO-HIV for AIDS-related diarrhea; CRO-ID for acute infectious diarrhea; and CRO-PED for pediatric diarrhea. It offers its products for D-IBS, HIV, acute-cholera, and pediatric markets. The company was founded in 2001 and is based in San Francisco, California. It has a subsidiary location in Mumbai, India.

from http://www.napopharma.com/

Research Grants 2 show all


$477.6K
2006

$111.4K
2007

Patents 124show all

  • 32
    A61K - Preparations for medical, dental, or toilet purposes
  • 8
    Y02A - Technologies for adaptation to climate change

Clinical Trials 3show all

2Phase 41Phase 2

SEC Filings show all


6
D

Contact Information

185 Berry Street Suite 1300
San Francisco, CA 94107
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$12,081,86911-502017-01-03Acquired

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2011-06-22$2,996,869Series Unknown
2010-10-27$3,360,000Series Unknown
2009-05-12$500,000Series Unknown
2011-10-27$3,087,500Series Unknown
2017-01-03$2,000,000Debt FinancingKingdon Capital
2014-06-06$137,500Debt Financing

SEC Form D Funding Events

DateOfferedSoldType
2014-06-06$137,500$137,500Debt, Option to Acquire, Security to be Acquired, Other
2011-10-27$5,000,000$3,087,500Equity
2011-06-22$6,000,000$2,996,869Equity, Debt, Other
2010-10-27$8,900,000$3,360,000Equity, Option to Acquire
2009-07-09$500,000$500,000Equity
2009-03-16Unknown Unknown Other (Paper Filing)

Key Executives

  • Lisa Conte
    Executive Officer
  • Charles Thompson
    Executive Officer
  • Steven King
    Executive Officer
  • Pravin Chaturvedi
    Executive Officer
  • Sir William Young
    Director
  • Gregory Stock
    Director
  • Thomas Van Dyck
    Director
  • Jack Van Hulst
    Director
  • Pravi Chaturvedi
    Executive Officer
  • Dennis Fenton
    Director
  • Joshua Mailman
    Director
  • Richard Fields
    Director